,Outcomes,Arm 1,Arm 2
0,intervention,olanzapine,haloperidol
1,responders according to the CGI Improvement item,Five of six,three of six

,Outcomes

,Outcomes,Arm 1,Arm 2
0,intervention,secretin,placebo
1,ADOS social-communication total score,-0.6 +/- 1.4,-0.8 +/- 2.9

,Outcomes

,Outcomes,Arm 2,Arm 1
0,intervention,placebo,risperidone
1,randomly assigned,52,49 children

,Outcomes

,Outcomes,Arm 2,Arm 1
0,intervention,placebo,risperidone
1,reduction in the Irritability score,14.1 percent,56.9 percent

,Outcomes

,Outcomes,Arm 1,Arm 2
0,intervention,risperidone,placebo
1,CGI-I scale,34 of 49,6 of 52

,Outcomes

,Outcomes,Arm 1,Arm 2
0,intervention,Risperidone,placebo
1,average weight gain,2.7+/-2.9 kg,0.8+/-2.2 kg

,Outcomes

,Outcomes,Arm 1,Arm 2
0,intervention,risperidone-treated,placebo-treated
1,irritability score,64 %,31 %

,Outcomes

,Outcomes,Arm 1,Arm 2
0,intervention,risperidone-treated,placebo
1,global improvement in their condition,87 %,40 %

,Outcomes

,Outcomes,Arm 1,Arm 2
0,intervention,risperidone,placebo
1,Somnolence,72.5 %,7.7 %

,Outcomes

,Outcomes,Arm 1,Arm 2
0,intervention,fluvoxamine-treated,placebo
1,responders,( 53 % ) of 15 patients,none of 15

,Outcomes

,Outcomes,Arm 1,Arm 2
0,intervention,FM,CHVP patients
1,Median FFS,36 months,19 months

,Outcomes

,Outcomes,Arm 1,Arm 2
0,intervention,IT methotrexate group,triple IT therapy group
1,Processing Speed Index score in the below-average range,19.5 %,6.9 %

,Outcomes

,Outcomes,Arm 1,Arm 2
0,intervention,AMB,FLU
1,successfully completed prophylaxis,58 % of the 36 patients,80 % of the 41 patients

,Outcomes

,Outcomes,Arm 1,Arm 2
0,intervention,tamoxifen,placebo
1,fatal myocardial infarction,1.75 ( 0.44 to 8.13 ),
2,on,6074,6072
3,unstable angina,0.69 ( 0.29 to 1.57 ),
4,severe angina,0.83 ( 0.32 to 2.10 ),
5,risk ratios ( 95 % confidence intervals [ CIs ] ),1.75 ( 0.44 to 8.13 ),
6,nonfatal myocardial infarction,1.11 ( 0.55 to 2.28 ),

,Outcomes

,Outcomes,Arm 1,Arm 2
0,intervention,tamoxifen,placebo
1,fatal myocardial infarction,0.00 ( 0 to 1.58 ),
2,severe angina,1.39 ( 0.23 to 9.47 ),
3,on,516,532
4,nonfatal myocardial infarction,1.25 ( 0.32 to 5.18 ),
5,risk ratios ( 95 % CIs ),1.39 ( 0.23 to 9.47 ),
6,unstable angina,2.26 ( 0.87 to 6.55 ),

,Outcomes

,Outcomes,Arm 1
0,intervention,psychosocial therapy
1,Risk of cardiovascular death,86 %

,Outcomes

,Outcomes,Arm 2
0,intervention,control
1,cardiovascular deaths,Six of the seven

,Outcomes

,Outcomes,Arm 1
0,intervention,therapy group
1,risk of all-cause mortality,62 %

,Outcomes

,Outcomes,Arm 1,Arm 2
0,intervention,therapy group,control group
1,deaths,three,eight

,Outcomes

,Outcomes,Arm 1,Arm 2
0,intervention,losartan,captopril
1,target dose,50 mg,50 mg

,Outcomes

,Outcomes,Arm 1,Arm 2
0,intervention,losartan,captopril
1,deaths,499 ( 18 % ),447 ( 16 % )

,Outcomes

,Outcomes,Arm 1,Arm 2
0,intervention,losartan,captopril
1,cardiovascular deaths,"420 , 15 %","363 , 13 %"

,Outcomes

,Outcomes,Arm 1,Arm 2
0,intervention,losartan,captopril
1,fewer patients discontinuing medication,17,23 %

,Outcomes

,Outcomes,Arm 2
0,intervention,placebo
1,incidence of ICD therapies per patient-year,36

,Outcomes

,Outcomes,Arm 1
0,intervention,metoprolol CR/XL
1,deceleration time of the early mitral filling wave ( E ),189 to 246 ms
2,left ventricular ejection fraction,0.26 to 0.31
3,duration of the late mitral filling wave ( A ),122 to 145 ms
4,time velocity integral of E-wave,8.7 to 11.2 cm

,Outcomes

,Outcomes,Arm 2
0,intervention,placebo
1,changes,No

,Outcomes

,Outcomes,Arm 1,Arm 2
0,intervention,Bronchodilators,controls
1,reduced peripheral airways resistance,0.38,0.19

,Outcomes

,Outcomes,Arm 1
0,intervention,Magnesium
1,reduced the shivering threshold,36.3 [ SD 0.4 ] degrees C

,Outcomes

,Outcomes,Arm 1,Arm 2
0,intervention,HBI,usual care group
1,unplanned hospitalization,677,824

,Outcomes

,Outcomes

,Outcomes

,Outcomes,Arm 1
0,intervention,CCM
1,increased LV peak +dP/dt,10.1 +/- 1.5 %

,Outcomes

,Outcomes

,Outcomes

,Outcomes,Arm 1,Arm 2
0,intervention,SES,PES
1,rates of MACEs,5.9 % ( n = 5 ),9.5 % ( n = 8 )
2,definite stent thrombosis,1.2 % ( n = 1,3.6 % ( n = 3

,Outcomes

,Outcomes,Arm 1
0,intervention,prophylaxis study group
1,duplex scans,109

,Outcomes

,Outcomes,Arm 1
0,intervention,coumadin
1,excessive blood loss,5.7 %

,Outcomes

,Outcomes,Arm 1
0,intervention,nonrandomized group
1,clinically detectable proximal deep vein thrombosis,One of the 219 patients

,Outcomes

,Outcomes

,Outcomes

,Outcomes,Arm 1,Arm 2
0,intervention,transfusions,standard
1,randomly assigned,63,67

,Outcomes

,Outcomes,Arm 1,Arm 2
0,intervention,transfusion,standard-care
1,dropped out,Ten patients,
2,crossed over,,two patients

,Outcomes

,Outcomes,Arm 2,Arm 1
0,intervention,standard-care group,transfusion group
1,cerebral infarctions,10,
2,intracerebral hematoma,1,
3,infarction,,1

,Outcomes

,Outcomes

,Outcomes

,Outcomes,Arm 1,Arm 2
0,intervention,acarbose,placebo
1,responders,20/24 patients,10/19 patients

,Outcomes

,Outcomes,Arm 1,Arm 2
0,intervention,acarbose,placebo
1,mean daily insulin dose after 24 weeks of treatment,16.4 +/- 10.1 IU,22.4 +/- 12.2 IU

,Outcomes

,Outcomes,Arm 1,Arm 2
0,intervention,enalapril,placebo
1,metabolic effect of glibenclamide,229 +/- 173,137 +/- 44

,Outcomes

,Outcomes,Arm 1
0,intervention,enalapril
1,maximal metabolic effect of glibenclamide,5.2 +/- 1.9

,Outcomes

,Outcomes,Arm 1,Arm 2
0,intervention,enalapril,placebo
1,total metabolic effect of glibenclamide,1267 +/- 334,1286 +/- 249

,Outcomes

,Outcomes

,Outcomes

,Outcomes,Arm 1,Arm 2
0,intervention,intervention,control
1,BP,-4.2 mmHg ( 95 % CI -12.4 to 3.9 ),/-2.6 mmHg ( 95 % CI -8.4 to 3.3 )

,Outcomes

,Outcomes,Arm 1
0,intervention,GLN
1,in-hospital deaths,14

,Outcomes

,Outcomes,Arm 1,Arm 2
0,intervention,GLN,GLY placebo
1,Acute graft us host disease,1 of 10,3 of 8

,Outcomes

,Outcomes,Arm 1,Arm 2
0,intervention,20 mg,50-mg
1,investigator,40.5 %,36.4 %
2,independent review,42.9 %,27.3 %

,Outcomes

,Outcomes,Arm 1
0,intervention,20 mg
1,investigator,64.3 %
2,independent,59.5 %

,Outcomes

,Outcomes,Arm 1,Arm 2
0,intervention,20,50 mg
1,Mean observed steady-state plasma concentrations,3.62,7.48

,Outcomes

,Outcomes,Arm 1,Arm 2
0,intervention,tourniquet,control
1,transfusion rates,7 %,79 %

,Outcomes

,Outcomes,Arm 1,Arm 2
0,intervention,fulvestrant,anastrozole
1,died,319 ( 74.5 % ),322 ( 76.1 % )

,Outcomes

,Outcomes,Arm 1,Arm 2
0,intervention,fulvestrant,anastrozole
1,median overall survival,27.4 months,27.7 months

,Outcomes

,Outcomes,Arm 1,Arm 2
0,intervention,q.d,b.i.d
1,15-year actuarial locoregional recurrence rate,7 %,12 %

,Outcomes

,Outcomes,Arm 1,Arm 2
0,intervention,q.d,b.i.d
1,rates of severe acute toxicity,4 %,5 %
2,moist desquamation developed,,42 %

,Outcomes

,Outcomes,Arm 1,Arm 2
0,intervention,q.d,b.i.d.
1,15-year actuarial rate of severe late RT complications,6 %,11 %

,Outcomes

,Outcomes,Arm 1,Arm 2
0,intervention,instruction,control
1,breast cancers detected,864,
2,breast cancer deaths,133,130
3,breast cancers were detected,,896

,Outcomes

,Outcomes,Arm 2,Arm 1
0,intervention,exemestane,tamoxifen
1,daily hot flashes increasing from baseline,7 %,33 %

,Outcomes

,Outcomes,Arm 1,Arm 2
0,intervention,group A,B
1,objective response rate,18 %,27.5 %

,Outcomes

,Outcomes,Arm 2
0,intervention,group B
1,rate and grade 3 and 4 neutropenia,23

,Outcomes

,Outcomes,Arm 1
0,intervention,tented
1,mean duration of air leak,4.9 +/- 1.79
2,hospital stay cost per patient,3840 +/- 298
3,length of postoperative in-hospital stay in days,9.4 +/- 1.86
4,number of days of a chest tube duration,7.3 +/- 1.14

,Outcomes

,Outcomes,Arm 1,Arm 2
0,intervention,local,central evaluations
1,HER2 overexpression/amplification,37.3 % ( 91/244 ),17.9 % ( 41/229 )

,Outcomes

,Outcomes

,Outcomes

,Outcomes,Arm 1,Arm 2
0,intervention,PSA-D,PSA-T
1,area under the ROC curve,0.77,0.79

,Outcomes

,Outcomes,Arm 1,Arm 2
0,intervention,arm A,arm B
1,response rates,22.0,28.9 %

,Outcomes

,Outcomes,Arm 1,Arm 2
0,intervention,arm A,arm B
1,Median time to treatment failure,3.6 months,4.8 months

,Outcomes

,Outcomes,Arm 1,Arm 2
0,intervention,arm A,arm B
1,Median time to progression,4.1 months,5.5 months

,Outcomes

,Outcomes,Arm 1,Arm 2
0,intervention,arm A,arm B
1,Median survival time,15.5 months,18.8 months

,Outcomes

,Outcomes,Arm 2,Arm 1
0,intervention,bimatoprost,latanoprost
1,ocular hyperaemia,22 subjects (37.9%),13 subjects (22.4%)

,Outcomes

,Outcomes,Arm 2,Arm 1
0,intervention,TRA/TIM group,TRA/TIM BAK-free group
1,most common drug-related adverse event was hyperemia of the eye (ocular hyperemia and conjunctival hyperemia combined),13.0%,11.8%

,Outcomes

,Outcomes,Arm 1,Arm 2
0,intervention,350-,500-
1,postoperative visual acuities remained within one line of the preoperative visual acuities or improved,62%,66%

,Outcomes

,Outcomes,Arm 1,Arm 2
0,intervention,T2345,BPL
1,global subjective ocular symptom score,0.18,0.46

,Outcomes

,Outcomes,Arm 1,Arm 2
0,intervention,Brimonidine,timolol
1,reduction in intraocular pressure,6.5 mm Hg,
2,mean peak reduction in IOP,,6.1 mm Hg

,Outcomes

,Outcomes,Arm 1,Arm 2
0,intervention,alginate,standard
1,mean reductions from baseline in intraocular pressure,6.32+/-2.87,5.67+/-3.30

,Outcomes

,Outcomes,Arm 1,Arm 2
0,intervention,BTFC,TTFC
1,Mean IOP reductions,11.17,7.89

,Outcomes

,Outcomes,Arm 1,Arm 2
0,intervention,brimonidine-timolol,timolol
1,mean additional reduction from latanoprost-treated baseline IOP,8.3 mmHg (35.5%),6.2 mmHg (27.0%)

,Outcomes

,Outcomes,Arm 1,Arm 2
0,intervention,BSS Plus,Ringer
1,CV increase,23.0 ± 3.0%,20.2 ± 4.0%

,Outcomes

,Outcomes,Arm 2,Arm 1
0,intervention,latanoprost/timolol,bimatoprost
1,mean IOP levels,13.83,16.16

,Outcomes

,Outcomes,Arm 1,Arm 2
0,intervention,brimonidine,latanoprost
1,enrolled,66,61

,Outcomes

,Outcomes,Arm 1,Arm 2
0,intervention,tafluprost,timolol
1,conjunctival hyperemia,4.4%,1.2%

,Outcomes

,Outcomes,Arm 1,Arm 2
0,intervention,latanoprost plus timolol group,dorzolamide plus timolol group
1,mean diurnal intraocular pressure reduction after 3 months,-7.06 mm Hg,-4.44 mm Hg

,Outcomes

,Outcomes,Arm 1,Arm 2
0,intervention,study group,control group
1,mean baseline intraocular pressure,23.8 +/- 12.6 mmHg,25.9 +/- 10.6 mmHg

,Outcomes

,Outcomes,Arm 1,Arm 2
0,intervention,Ahmed,Baerveldt
1,Mean durations of follow-up,20.0 months,22.9 months

,Outcomes

,Outcomes,Arm 1,Arm 2
0,intervention,Ahmed,Baerveldt
1,Cumulative successes,0.73,0.92

,Outcomes

,Outcomes,Arm 1,Arm 2
0,intervention,laser,control
1,proportion of eyes started on medical treatment,8 eyes (15%),9 eyes (17%)

,Outcomes

,Outcomes,Arm 1,Arm 2
0,intervention,study group,control group
1,completed the study (follow-up of 12 mo),18,25

,Outcomes

,Outcomes,Arm 1,Arm 2
0,intervention,latanoprost group,dorzolamide/timolol group
1,mean (standard error of mean [SE]) IOP reductions,month 3 was 7.3 (0.4),7.4 (0.3)

,Outcomes

,Outcomes,Arm 1,Arm 2
0,intervention,fixed-combination,latanoprost
1,at least 1 treatment-emergent AE,10.9%,12.1%

,Outcomes

,Outcomes,Arm 1,Arm 2
0,intervention,brimonidine,timolol
1,Clinical success,71% (75/106),70% (73/105)

,Outcomes

,Outcomes,Arm 1,Arm 2
0,intervention,lidocaine,BSS
1,pain,45.1%,53.7%

,Outcomes

,Outcomes,Arm 2
0,intervention,dorzolamide
1,corresponding figures,5.6 (2.6) mm Hg

,Outcomes

,Outcomes,Arm 1,Arm 2
0,intervention,SLT,ALT
1,mean decrease in IOP,5.86 mm Hg,6.04 mm Hg

,Outcomes

,Outcomes,Arm 1,Arm 2
0,intervention,350-mm2,500-mm2
1,Visual acuities were better or remained the same,50%,46%

,Outcomes

,Outcomes,Arm 1,Arm 2
0,intervention,viscocanalostomy group,trabeculectomy group
1,Mean baseline IOP,24.0+/-2.0 mmHg,23.7+/-2.6 mmHg

,Outcomes

,Outcomes,Arm 1,Arm 2
0,intervention,standard trabeculectomy,microtrabeculectomy
1,mean intraocular pressure and cumulative probability of failure,12.4 ± 4.6 mmHg and 0.28,11.5 ± 3.6 mmHg and 0.27

,Outcomes

,Outcomes,Arm 1,Arm 2
0,intervention,brimonidine,latanoprost
1,clinical success at month 3,91%,74%

,Outcomes

,Outcomes,Arm 2,Arm 1
0,intervention,Ex-PRESS,trabeculectomy
1,mean pre-operative IOP decreased,28.1 (± 9.0) to 15.7 (± 1.8) mm Hg,31.1 (± 14.2) to 16.2 (± 1.5) mm Hg

,Outcomes

,Outcomes,Arm 1,Arm 2
0,intervention,Latanoprost 0.005%,latanoprost 0.0015%
1,reduced IOP (+/- SEM),9.8 +/- 0.9 mm Hg,6.7 +/- 0.9 mm Hg

,Outcomes

,Outcomes,Arm 1
0,intervention,ologen
1,absolute success rate,50%

,Outcomes

,Outcomes,Arm 1,Arm 2
0,intervention,Latanoprost,bimatoprost
1,reduced IOP (mean (SD)),8.4 (3.8) mm Hg,8.9 (3.9) mm Hg

,Outcomes

,Outcomes,Arm 1,Arm 2
0,intervention,lidocaine,BSS
1,median pain score (range),0.0,1.0

,Outcomes

,Outcomes,Arm 1,Arm 2
0,intervention,MMC,control
1,probability of success at 18 months,62%,67%

,Outcomes

,Outcomes,Arm 1,Arm 2
0,intervention,brimonidine,timolol
1,clinical success rate,86.2%,81.8%

,Outcomes

,Outcomes,Arm 1,Arm 2
0,intervention,350-,500-
1,anterior uveitis,14%,11%
2,serous choroidal effusion,16%,32%
3,strabismus,16%,19%

,Outcomes

,Outcomes,Arm 2,Arm 1
0,intervention,latanoprost,dorzolamide/timolol
1,mean daytime diurnal IOP,18.4 mmHg,17.4 mmHg

,Outcomes

,Outcomes,Arm 1,Arm 2
0,intervention,5-FU,MMC
1,intraocular pressures,14.2 +/- 5.5,
2,less than or equal to 12 mmHg,21.1%,60.0%

,Outcomes

,Outcomes,Arm 1,Arm 2
0,intervention,laser,control
1,converted to glaucoma,15%,6%

,Outcomes

,Outcomes,Arm 1
0,intervention,alginate
1,blurred vision sensation,2 out of 74 patients

,Outcomes

,Outcomes,Arm 1,Arm 2
0,intervention,group A,group B
1,shallower anterior chamber,14 eyes,7 eyes

,Outcomes

,Outcomes,Arm 1,Arm 2
0,intervention,latanoprost,timolol
1,Responder rates,72%,57%

,Outcomes

,Outcomes,Arm 1,Arm 2
0,intervention,MMC,OLO
1,mean preoperative IOP,26.5 (±5.2),27.3 (±6.0)

,Outcomes

